Moneycontrol PRO
LAMF
LAMF

Dr Reddys Laboratories shares sees high volume trading amid slight dip

Dr Reddys Laboratories' stock movement today reflects a combination of high investor interest and a slight price adjustment. The company's financial performance showcases a pattern of consistent growth, reinforcing its position in the pharmaceutical sector.
May 07, 2025 / 13:41 IST
Disclaimer This is an AI-assisted live blog with updates sourced from multiple news outlets and agencies Disclaimer
Mazagon Dock, HAL, other defence stocks see profit booking on India-Pak de-escalation hopes.

Dr Reddys Laboratories experienced high trading volumes during today's session, accompanied by a marginal decrease of 0.12 percent. The stock is currently priced at Rs 1159.00. The increased trading activity has drawn attention to the pharmaceutical giant, which is a component of both the NIFTY 50 and NIFTY 100 indices.

Financial Performance Overview

A review of Dr Reddys Laboratories' financial performance reveals consistent growth in revenue and net profit over the recent years.

Quarterly Highlights:

QuarterRevenue (Cr)Net Profit (Cr)EPS
Dec 2023Rs 7,236.80Rs 1,378.20Rs 82.94
Mar 2024Rs 7,113.80Rs 1,306.30Rs 78.66
Jun 2024Rs 7,696.10Rs 1,386.50Rs 83.61
Sep 2024Rs 8,038.20Rs 1,335.80Rs 80.45
Dec 2024Rs 8,381.20Rs 1,400.00Rs 16.97

Annual Performance:

YearRevenue (Cr)Net Profit (Cr)EPSBVPSROEDebt to Equity
2020Rs 17,517.00Rs 1,969.90Rs 122.22Rs 938.5612.980.11
2021Rs 19,047.50Rs 1,903.60Rs 117.67Rs 1,060.2011.060.15
2022Rs 21,545.20Rs 2,112.20Rs 131.57Rs 1,154.5911.350.16
2023Rs 24,669.70Rs 4,470.30Rs 271.47Rs 1,397.7319.350.05
2024Rs 28,011.10Rs 5,563.20Rs 335.22Rs 1,693.9319.740.06

The company has demonstrated consistent growth in key financial metrics, as highlighted by both quarterly and annual data. Revenue has steadily increased, and net profit has shown a strong upward trajectory. According to a Moneycontrol analysis as of 2025-04-30, the sentiment for the stock is bullish.

Dr Reddys Laboratories' stock movement today reflects a combination of high investor interest and a slight price adjustment. The company's financial performance showcases a pattern of consistent growth, reinforcing its position in the pharmaceutical sector.

Alpha Desk
first published: May 7, 2025 01:41 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347